Bradley Pharmaceuticals Acquires P&G's Brontex Product Line

Bradley Pharmaceuticals, Inc. has acquired the Brontex product line, trademark and existing inventory from Procter & Gamble Pharmaceuticals. Brontex, a cough suppressant containing the active ingredients codeine phosphate and guaifenesin, was launched by P&G in September 1994. The product will be marketed by BradPharma's Kenwood Therapeutics division.

Daniel Glassman, chairman and CEO, Bradley Pharmaceuticals, said, "This highly effective cough suppressant adds to our presence in the respiratory market with a product line that includes: Deconamine antihistamine/decongestant for symptomatic relief from colds, allergies, sinusitis and URI; Tyzine topical nasal decongestant; and the newly introduced ENTsol hypertonic nasal wash line."

For more information: Daniel Glassman, chairman and CEO, Bradley Pharmaceuticals, Inc. Telephone: 973-882-1505, ext. 210.